

INNOVATIVE RESEARCH, CUTTING-EDGE THERAPIES

Through Specialty Care Centers of UPMC Hillman Cancer Center

Clinical trials are an opportunity for your patients to benefit from advances being made at UPMC Hillman Cancer Center, which is recognized both nationally and internationally for its translational research programs.

For a complete list of current research initiatives, or for more information about patient care, call **412-623-4861** or visit **Hillman.UPMC.com**.



UPMC | **HILLMAN
CANCER CENTER**

Ongoing Clinical Trials

Adult Brain Cancer

UPCI 16-185 Individualized screening trial of innovative glioblastoma therapy (INSIGHT).

UPCI 16-024 Phase I trial of Anti-LAG-3 or Anti-CD137 alone and in combination with Anti-PD-1 in patients with recurrent GBM.

Bladder Cancer

UPCI 15-193: A Phase 3 randomized, double-blind, multi-center study of adjuvant Nivolumab versus placebo in subjects with high risk invasive urothelial carcinoma.

UPCI 16-188: An open label, non-randomized, Phase I dose escalation study to characterize safety, tolerability, pharmacokinetics and maximum tolerated dose of BAY 1163877 in subjects with refractory, locally advanced or metastatic solid tumors.

UPCI 17-007: A Phase 1 Study of the safety and pharmacokinetics of escalating doses of ASG-22CE given as monotherapy in subjects with metastatic urothelial cancer and other malignant solid tumors that express Nectin-4.

Breast Cancer

UPCI 17-016 (S1418) A Randomized, Phase III trial to evaluate the efficacy and safety of MK-3475 (Pembrolizumab) as adjuvant therapy for triple negative receptor-negative BC with >1 cm residual invasive cancer or positive lymph nodes (>pN1mic) after neo-adjuvant chemotherapy.

UPCI 14-070 A Randomized Phase III Trial of endocrine therapy plus Entinostat/Placebo in postmenopausal patients with hormone receptor-positive advanced breast cancer.

Colorectal Cancer

UPCI 16-095: A Phase III randomized placebo-controlled study evaluating regorafenib following completion of standard chemotherapy for patients with stage III colon cancer (ARGO).

Esophageal/Gastric Cancer

UPCI 15-182: A randomized, active-controlled, partially blinded, biomarker select, Phase III clinical trial of pembrolizumab as monotherapy and in combination with cisplatin+5-fluorouracil versus placebo+cisplatin+5-fluorouracil as first-line treatment in subjects with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.

GI Cancer

UPCI 15-181: A Phase III study of pembrolizumab (MK-3475) vs. chemotherapy in microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) stage IV colorectal carcinoma (KEYNOTE-177).

Head and Neck Cancer

UPCI 15-185: A Phase I/IIa dose escalation and cohort expansion study of the safety, tolerability, and efficacy of Anti-LAG-3 monoclonal antibody (BMS-986016) administered alone and in combination with Anti-PD-1 monoclonal antibody (Nivolumab, BMS-936558) in advanced solid tumors.

UPCI 15-132: A randomized, Phase II study evaluating concurrent or sequential fixed-dose of pembrolizumab in combination with cisplatin and intensity modulated radiotherapy (IMRT) in intermediate or high-risk, previously untreated, locally advanced head and neck cancer.

Hematology-Oncology

UPCI 15-002: A Phase III randomized, placebo-controlled, double-blind study of oral ixazomib maintenance therapy after initial therapy in patients with newly diagnosed multiple myeloma not treated with stem cell transplant.

Kidney Cancer

UPCI 17-019: EA8143: A Phase 3 randomized study comparing perioperative Nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).

UPCI 16-074: A multi-center, open-label, randomized Phase II study of AGS-16C3F vs. axitinib in metastatic renal cell carcinoma.

UPCI 16-206: A Phase III, multicenter, randomized, placebo-controlled, double-blind study of Atezolizumab (ANTI-PD-L1 Antibody) as adjuvant therapy in patients with renal cell carcinoma at high risk of developing metastasis following nephrectomy.

Leukemia

UPCI 15-101: A Phase II study of pembrolizumab as post-remission > 60 AML not transplant candidates.

UPCI 15-060: A Phase II study evaluating selective depletion of CD45RA+ T cells from allogeneic peripheral blood stem cell grafts from HLA-matched related and unrelated donors for prevention of GVHD.

Liver Cancer

UPCI 16-065: A Phase III study of pembrolizumab (MK-3475) vs. best supportive care as second-line therapy in subjects with previously systemically treated advanced hepatocellular carcinoma (KEYNOTE-240).

Lung Cancer

UPCI 16-153 A Phase II clinical trial evaluating the efficacy of Atezolizumab in advanced non-small cell lung cancer (NSCLC) patients previously treated with PD-1-directed therapy.

UPCI 16-054 A phase II clinical trial evaluating the safety and efficacy of Durvalumab (MEDI4736) as 1st line therapy in advanced non-small cell lung cancer (NSCLC) patients with Eastern Cooperative Oncology Group (ECOG) performance status of 2.

Lymphoma

UPCI 16-070: A Phase III randomized open label trial to compare pembrolizumab with brentuximab vedotin in subjects with relapsed or refractory classical Hodgkin lymphoma.

UPCI 16-098: A Phase II study of AT13387 in refractory and/or relapsed ALK + ALCL, MCL and BCL 6 + DLBCL.

Melanoma

UPCI 16-126: A Phase II multicenter, 3-cohort study to assess the safety and efficacy of autologous tumor infiltrating lymphocytes (LN-144) for treatment of patients with metastatic melanoma.

UPCI 15-186: A multicenter, open-label, Phase 1B clinical study of CMP-001 in combination with pembrolizumab in subjects with advanced melanoma.

UPCI 17-085: A Phase 1 dose escalation and cohort expansion study of TSR-022, an anti-TIM-3 monoclonal antibody, in patients with advanced solid tumors.

Neuroendocrine Cancer

UPCI 15-179: Randomized Phase II study of cisplatin and etoposide versus temozolomide and capecitabine in patients with advanced G3 non-small cell gastroenteropancreatic neuroendocrine carcinomas.

Pancreatic Cancer

UPCI 15-176: A Phase III, randomized, double-blind, placebo-controlled, multicenter study of PEGylated recombinant human hyaluronidase (PEGPH20) in combination with nab-paclitaxel plus gemcitabine compared with placebo plus nab-paclitaxel and gemcitabine in subjects with hyaluronan-high stage IV previously untreated pancreatic ductal adenocarcinoma.

UPCI 16-203: A randomized phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line Gemcitabine containing regimen.

Endometrial/Peritoneal/Ovarian Cancers

UPCI 16-136 A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of Cediranib and Olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline *BRCA* mutation.

UPCI 17-062 Phase 2 study of Atezolizumab in combination with Bevacizumab in patients with recurrent, persistent, or metastatic cervical cancer.

Prostate Cancer

UPCI 16-192: Phase Ib/II trial of Pembrolizumab (MK-3475) combination therapies in metastatic castration-resistant prostate cancer (mCRPC) (KEYNOTE-365).

UPCI 16-195: A Phase III, multicenter, randomized, study of Atezolizumab (Anti-Pd-L1 Antibody) in combination with Enzalutamide Versus Enzalutamide alone in patients with metastatic castration-resistant prostate cancer after failure of an androgen synthesis inhibitor and failure of, ineligibility for, or refusal of a Taxane regimen.

Sarcoma

UPCI 12-104: A Phase IB of II study of vorinostat in combination with gemcitabine and docetaxel in advanced sarcoma.

UPCI 17-063: An open-label, multicenter, Phase 1a/1b study of Olaratumab (LY3012207) plus Pembrolizumab (MK3475) in patients with unresectable locally advanced or metastatic soft tissue sarcoma who have failed standard treatments.

Thyroid

UPCI 16-121: A phase II study of molecular markers to guide extent of initial thyroid surgery for patients with newly diagnosed papillary thyroid cancer

For a complete list of clinical trials please call 412-623 4861.